论文部分内容阅读
目的检测多发性肌炎(polymyositis,PM)患者血清中炎症因子白细胞介素6(IL-6)的水平,分析IL-6与PM患者临床及实验室相关指标、糖皮质激素(GC)治疗的关系,探讨炎症因子IL-6等在PM发病机制及治疗中的作用。方法选择2010年4月—2014年1月在浙江省人民医院采用酶联免疫吸附法(ELISA)检测36例PM患者血清中IL-6以及TNF-α水平,并与同期10例健康体检者对照(健康对照组)。利用国际肌炎组织制定的炎性肌病评价工具,将患者分为活动期与缓解期2组。3组间计量资料比较采用方差分析,2组间计量资料比较采用t检验,组间计量资料相关性采用Spearman法。结果血清IL-6在多发性肌炎活动组[(19.67±7.16)pg/ml]、缓解组[(15.81±4.00)pg/ml]中的水平均显著高于健康对照组[(8.14±3.71)pg/ml,P<0.001],且活动组显著高于缓解组(P=0.043)。TNF-α在活动组[(114.44±36.04)pg/ml]、缓解组[(97.65±30.78)pg/ml]中的水平显著性高于健康对照组[(55.43±22.83)pg/ml,P<0.001],但活动组与缓解组比较差异无统计学意义(P=0.141)。分析发现血清IL-6水平与TNF-α水平呈显著正相关(r=0.709,P<0.001),与GC治疗量呈负相关(r=-0.573,P<0.001)。结论 IL-6可作为PM疾病活动评估及治疗中激素量的重要参考指标。
Objective To detect the level of interleukin 6 (IL-6) in sera of patients with polymyositis (PM) and to analyze the clinical and laboratory related indexes of IL-6 and PM, and to evaluate the effect of glucocorticoid Relationship, to explore the inflammatory cytokine IL-6 in the pathogenesis and treatment of PM role. Methods The levels of IL-6 and TNF-α in serum of 36 PM patients were detected by enzyme-linked immunosorbent assay (ELISA) in Zhejiang Provincial People’s Hospital from April 2010 to January 2014 and compared with 10 healthy controls (Healthy control group). Utilizing the evaluation tool of inflammatory myopathy developed by international myositis organization, the patients were divided into active group and remission group. Three groups of measurement data were compared using analysis of variance, measurement data between two groups using t test, measurement data between groups using Spearman method. Results The levels of serum IL-6 in polymyositis active group [(19.67 ± 7.16) pg / ml] and remission group [(15.81 ± 4.00) pg / ml] were significantly higher than those in healthy controls [(8.14 ± 3.71 ) pg / ml, P <0.001], and the activity group was significantly higher than the remission group (P = 0.043). The levels of TNF-α in the active group [(114.44 ± 36.04) pg / ml] and remission group [(97.65 ± 30.78) pg / ml] were significantly higher than those in the healthy control group [(55.43 ± 22.83) pg / <0.001]. However, there was no significant difference between active group and remission group (P = 0.141). The level of IL-6 in serum was positively correlated with TNF-α (r = 0.709, P <0.001), and negatively correlated with the amount of GC treatment (r = -0.573, P <0.001). Conclusion IL-6 can be used as an important reference for assessment of PM disease activity and hormone dose in treatment.